Clinical trial
Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer
NCT00451555 · Eli Lilly and Company, Industry · Completed
Key facts
| NCT number | NCT00451555 |
|---|---|
| Title | Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer |
| Official title | A Randomized, Double-Blind, Phase II Trial of Fulvestrant Plus Enzastaurin Versus Fulvestrant Plus Placebo in Aromatase Inhibitor-Resistant Metastatic Breast Cancer |
| Lead sponsor | Eli Lilly and Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Breast Cancer |
| Intervention type | Drug |
| Interventions | enzastaurin, placebo, fulvestrant |
| Enrollment | 156 |
| Start date | Apr 11, 2007 |
| Primary completion | Dec 28, 2010 |
| Completion | Oct 18, 2018 |
| First posted | Mar 23, 2007 |
| Last update posted | Nov 1, 2019 |
| Countries | France, Germany, Italy, Netherlands, Spain |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: